IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: A meta-analysis

Journal of Viral Hepatitis

Volumn 20, Issue 6, 2013, Pages 377-384

  Rangnekar, A S ^a   Fontana, R J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

genetic polymorphisms; hepatitis C; peginterferon; ribavirin; sustained virologic response

Indexed keywords

ANTIVIRUS AGENT; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; ASIAN; CAUCASIAN; DISEASE ASSOCIATION; EMBASE; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDLINE; META ANALYSIS; MICROBIOLOGICAL PARAMETERS; PRIORITY JOURNAL; RAPID VIROLOGIC RESPONSE; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; ODDS RATIO; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877578599     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12039     Document Type: Article

References (29)

1. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
2. Rangnekar AS, Fontana RJ,. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012; 36: 104-114.
3. Mangia A, Thompson AJ, Santoro R, et al,. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827, 7 e1.
4. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al,. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.
5. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR,. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther 2012; 36: 91-103.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
7. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
8. Whiting PF, Rutjes AW, Westwood ME, et al,. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536.
9. Owens DK, Lohr KN, Atkins D, et al,. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010; 63: 513-523.
10. Stattermayer AF, Stauber R, Hofer H, et al,. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.
11. Sarrazin C, Susser S, Doehring A, et al,. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
12. Bochud PY, Bibert S, Negro F, et al,. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011; 55: 980-988.
13. Moghaddam A, Melum E, Reinton N, et al,. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
14. Fattovich G, Covolo L, Bibert S, et al,. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-1172.
15. Bitetto D, Fattovich G, Fabris C, et al,. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118-1126.
16. de Rueda PM, Lopez-Nevot MA, Saenz-Lopez P, et al,. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 2011; 106: 1246-1254.
17. Amanzada A, Goralczyk A, Moriconi F, et al,. Ultra-rapid virological response, young age, low gamma-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-alpha(2a) monotherapy. Dig Dis Sci 2011; 56: 3296-3304.
18. Halfon P, Bourliere M, Ouzan D, et al,. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol 2011; 23: 931-935.
19. Lindh M, Lagging M, Farkkila M, et al,. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-1752.
20. Kawaoka T, Hayes CN, Ohishi W, et al,. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-414.
21. Yu ML, Huang CF, Huang JF, et al,. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
22. Sakamoto N, Nakagawa M, Tanaka Y, et al,. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 2011; 83: 871-878.
23. Sinn DH, Kim YJ, Lee ST, et al,. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol 2011; 26: 1374-1379.
24. Ochi H, Maekawa T, Abe H, et al,. IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J Gen Virol 2011; 92: 1071-1081.
25. Mangia A, Santoro R, Minerva N, et al,. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.
26. von Wagner M, Huber M, Berg T, et al,. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527.
27. Alter MJ, Kruszon-Moran D, Nainan OV, et al,. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
28. Howell C, Jeffers L, Hoofnagle JH,. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119: 1385-1396.
29. Zeuzem S, Hultcrantz R, Bourliere M, et al,. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999.